Page 18 - Erişkinlerde Hastanede Gelişen Pnömoni Tanı ve Tedavi Uzlaşı Raporu

Türk Toraks Derneği Erişkinlerde Hastanede Gelişen Pnömoni Tanı ve Tedavisi Uzlaşı Raporu

88. Teramoto S, Fukuchi Y, Sasaki H, et al. High incidence of aspira- 105. Yang JW, Fan LC, Lu HW, et al. Efficacy and safety of long-term
tion pneumonia in community- and hospital-acquired pneumo- inhaled antibiotic for patients with noncystic fibrosis bronchiec-
nia in hospitalized patients: a multicenter, prospective study in tasis: a meta-analysis. Clin Respir J 2016;10:731-9.
Japan. J Am Geriatr Soc 2008;56:577-9. 106. Kollef MH. Hospital-acquired pneumonia and de-escalation of
89. Falagas ME, Tansarli GS, Ikawa K, et al. Clinical outcomes with antimicrobial treatment. Crit Care Med 2001;29:1473-5.
extended or continuous versus short-term intravenous infusion 107. Joung MK, Lee JA, Moon SY, et al. Impact of de-escalation the-
of carbapenems and piperacillin/tazobactam: a systematic revi- rapy on clinical outcomes for intensive care unit-acquired pne-
ew and meta-analysis. Clin Infect Dis 2013;56:272-82. umonia. Crit Care 2011;15:R79.
90. Dulhunty JM, Roberts JA, Davis JS, et al. Continuous infusion of be- 108. Garnacho-Montero J, Gutie´rrez- Pizarraya A, Escoresca-Ortega
ta-lactam antibiotics in severe sepsis: a multicenter double-blind, A, et al. Deescalation of empirical therapy is associated with
randomized controlled trial. Clin Infect Dis 2013;56:236-44. lower mortality in patients with severe sepsis and septic shock.
91. Lal A, Jaoude P, El-Solh AA. Prolonged versus Intermittent Infu- Intensive Care Med 2014;40:32-40.
sion of β-Lactams for the Treatment of Nosocomial Pneumonia: 109. Raman K, Nailor MD, Nicolau DP, et al. Early antibiotic dis-
A Meta-Analysis. Infect Chemother 2016;48:81-90. continuation in patients with clinically suspected ventilator-as-
92. Frippiat F, Musuamba FT, Seidel L, et al. Modelled target attain- sociated pneumonia and negative quantitative bronchoscopy
ment after meropenem infusion in patients with severe nosoco- cultures. Crit Care Med 2013;41:1656-63.
mial pneumonia: the PROMESSE study. J. Antimicrob Chemot- 110. Capellier G, Mockly H, Charpentier C, et al. Earlyonset venti-
her 2015;70:207-16. lator-associated pneumonia in adults randomized clinical trial:
93. Shiu JR, Wang E, Tejani AM, Wasdell M. Continuous versus comparison of 8 versus 15 days of antibiotic treatment. PLoS
intermittent infusions of antibiotics for the treatment of severe One 2012;7:e41290.
acute infections. In: Tejani AM, editors. Cochrane Database Syst 111. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of
Rev. Chichester, UK: John Wiley & Sons, Ltd, 2013. Available antibiotic therapy for ventilatorassociated pneumonia in adults:
at: http://doi.wiley.com/10.1002/14651858.CD008481.pub2. a randomized trial. JAMA 2003;290:2588-98.
Aralık 2016. 112. Dalhoff K, Ewig S, Gideline Development Group. Adult patients
94. Chu H, Zhao L, Wang M, et al. Sulbactam-based therapy for with nosocomial pneumonia: epidemiology, diagnosis, and tre-
Acinetobacter baumannii infection: a systematic review and atment. Dtsch Arztebl Int 2013;110:634-40.
meta-analysis. Brazilian J Infect Dis 2013;17:389-94. 113. Dimopoulos G, Poulakou G, Pneumatikos IA, et al. Short- vs
95. Ko WC, Lee HC, Chiang SR, et al. In vitro and in vivo acti- long-duration antibiotic regimens for ventilator-associated
vity of meropenem and sulbactam against a multidrug-resis- pneumonia: a systematic review and meta-analysis. Chest
tant Acinetobacter baumannii strain. J Antimicrob Chemother 2013;144:1759-67.
2004;53:393-5. 114. Garnacho-Montero J, Corcia-Palomo Y, Amaya-Villar R, et al.
96. Lee YT, Tsao SM, Hsueh PR. Clinical outcomes of tigecycline How to treat VAP due to MDR pathogens in ICU patients. BMC
alone or in combination with other antimicrobial agents for the Infect Dis 2014;14:135.
treatment of patients with healthcare-associated multidrug-re- 115. Montravers P, Harpan A, Guivarch E. Current and future con-
sistant Acinetobacter baumannii infections. Eur J Clin Microbiol siderations for the treatment of hospital-acquired pneumonia.
Infect Dis 2013;32:1211-20. Adv Ther 2016;33:151-66.
97. Tasbakan M, Pullukcu H, Sipahi O, et al. Is Tigecycline a good 116. Nair GB, Niederman MS. Ventilator-associated pneumonia: pre-
choice in the treatment of multidrug-resistant acinetobacter ba- sent understanding and ongoing debates. Intensive Care Med
umannii pneumonia? J Chemother 2011;23:345-9. 2015;41:34-48.
98. Taşbakan MS, Pullukçu H, Ekren PK, et al. Colistin use in ven- 117. Luna CM, Sarquis S, Niederman MS, et al. Is a strategy based on
tilator-associated pneumonia due to panresistant Pseudomo- routine endotracheal cultures the best way to prescribe antibi-
nas aeruginosa and Acinetobacter baumannii]. Mikrobiyol Bul otics in ventilator-associated pneumonia? Chest 2013;144:63-
2009;43:61-70. 71.
99. Kolaylı F, Semiz C, Vahaboglu H. In-vitro activity of oxymino- 118. Waters B, Muscedere J. A 2015 Update on Ventilator-Associated
cephalosporins with and without sulbactam against Class A Pneumonia: New Insights on Its Prevention, Diagnosis, and Tre-
Extended-spectrum β-lactamase producing E.coli. J Microbiol atment. Curr Infect Dis Rep 2015;17:496.
Infect Dis 2011;1:87-92. 119. Gibot S, Cravoisy A, Levy B, et al. Soluble triggering receptor
100. Karaiskos I, Giamarellou H. Multidrug-resistant and exten- expressed on myeloid cells and the diagnosis of pneumonia. N
sively drug-resistant Gram-negative pathogens: current and Engl J Med 2004;350:451-8.
emerging therapeutic approaches. Expert Opin Pharmacother 120. Grover V, Pantelidis P, Soni N, et al. A biomarker panel (Bios-
2014;15:1351-70. core) incorporating monocytic surface and soluble TREM-1 has
101. Oliva A, Gizzi F, Mascellino MT, et al. Bactericidal and syner- high discriminative value for ventilator associated pneumonia:
gistic activity of double-carbapenem regimen for infections cau- a prospective observational study. PLoS One 2014;9:e109686.
sed by carbapenemase-producing Klebsiella pneumoniae. Clin 121. Luyt CE, Guérin V, Combes A, et al. Procalcitonin kinetics as
Microbiol Infect 2016;22:147-53. a prognostic marker of ventilator-associated pneumonia. Am J
102. Oliva A, Scorzolini L, Castaldi D, et al. Double-carbapenem re- Respir Crit Care Med 2005;171:48-53.
gimen, alone or in combination with colistin, in the treatment of 122. Ramirez P, Garcia MA, Ferrer M, et al. Sequential measurements
infections caused by carbapenem-resistant Klebsiella pneumo- of procalcitonin levels in diagnosing ventilator-associated pneu-
niae (CR-Kp). J Infect 2017;74:103-6. monia. Eur Respir J 2008;31:356-62.
103. Cprek JB, Gallagher JC. Ertapenem-containing double-carbape- 123. Grover V, Pantelidis P, Soni N, et al. A biomarker panel (Bios-
nem therapy for treatment of infections caused by carbapenem- core) incorporating monocytic surface and soluble TREM-1 has
resistant klebsiella pneumoniae antimicrob. Antimicrob Agents high discriminative value for ventilator associated pneumonia:
Chemother 2015;60:669-73. a prospective observational study. PLoS One 2014;9:e10
104. Zampieri FG, Nassar Jr AP, Gusmao-Flores D, et al. Nebulized 124. Stolz D, Smyrnios N, Eggimann P, et al. Procalcitonin for redu-
antibiotics for ventilator-associated pneumonia: a systematic ced antibiotic exposure in ventilator-associated pneumonia: a
review and meta-analysis. Crit Care 2015;19:150. randomised study. Eur Respir J 2009;34:1364-75.